electroCoreECOR
ECOR
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
450% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 2
101% more capital invested
Capital invested by funds: $7.15M [Q3] → $14.4M (+$7.25M) [Q4]
39% more funds holding
Funds holding: 23 [Q3] → 32 (+9) [Q4]
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
9.97% less ownership
Funds ownership: 23.49% [Q3] → 13.52% (-9.97%) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$25
303%
upside
Avg. target
$26
311%
upside
High target
$26
319%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Ladenburg Thalmann Jeffrey Cohen 0% 1-year accuracy 0 / 1 met price target | 319%upside $26 | Buy Maintained | 13 Mar 2025 |
HC Wainwright & Co. Swayampakula Ramakanth 22% 1-year accuracy 45 / 203 met price target | 303%upside $25 | Buy Reiterated | 13 Mar 2025 |
Financial journalist opinion
Based on 6 articles about ECOR published over the past 30 days
Neutral
GlobeNewsWire
7 hours ago
electroCore to Participate at the Needham Virtual Healthcare Conference
ROCKAWAY, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate at the Needham Virtual Healthcare Conference taking place virtually on April 10, 2025.

Neutral
GlobeNewsWire
1 day ago
electroCore Extends VA Contract for Five Years
ROCKAWAY, N.J., March 31, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that electroCore has received a new Federal Supply Schedule (FSS) contract, with an effective date of June 15, 2025 and running through June 14, 2030.

Neutral
Seeking Alpha
2 weeks ago
electroCore, Inc. (ECOR) Q4 2024 Earnings Call Transcript
electroCore, Inc. (NASDAQ:ECOR ) Q4 2024 Results Conference Call March 12, 2025 5:30 PM ET Company Participants Dan Goldberger - CEO & Director Joshua Lev - Chief Financial Officer Conference Call Participants Anthony Vendetti - Maxim Group Tyler Bussian - Brookline Capital Operator [Call Starts Abruptly] As part of our ongoing efforts to reduce costs and drive profitability, management has opted to host this earnings call on Zoom rather than using a more costly service provider. This will be our first time hosting the call independently, so we appreciate your patience as we work through any potential technical issues.

Neutral
GlobeNewsWire
2 weeks ago
electroCore Announces Full Year 2024 Financial Results
Record f ull year 2024 net sales of $ 25.2 million increased 57% over $16.0 million for the full year 2023 driven by 85% annual growth of Rx gammaCore TM in the United States Department of Veteran Affairs and United States Department of Defense (VA) and 174% increase in Truvaga TM sales

Neutral
GlobeNewsWire
3 weeks ago
electroCore to Announce Fourth Quarter and Full Year Ended December 31, 2024 Financial Results on Wednesday, March 12, 2025
ROCKAWAY, N.J., March 06, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report its financial results for the fourth quarter and full year ended December 31, 2024, after market close on Wednesday, March 12, 2025.

Neutral
GlobeNewsWire
3 weeks ago
electroCore to Participate at Upcoming Investor Conferences
Management to Attend the 37th Annual Roth Conference and the LSI USA '25 Management to Attend the 37th Annual Roth Conference and the LSI USA '25

Neutral
GlobeNewsWire
1 month ago
electroCore, Inc. Announces Agreement with Spark Biomedical Inc. to Distribute Sparrow Ascent for Opioid Withdrawal
ROCKAWAY, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Sparrow Ascent™ by Spark Biomedical, an FDA cleared non-invasive transcutaneous auricular neuromodulation device available by prescription for the treatment of opioid withdrawal symptoms, will be distributed by electroCore, Inc. within certain Department of Veterans Affairs (VA) facilities.

Positive
Zacks Investment Research
1 month ago
electroCore (ECOR) Is a Great Choice for 'Trend' Investors, Here's Why
electroCore (ECOR) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Neutral
GlobeNewsWire
1 month ago
electroCore to Participate at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
ROCKAWAY, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today its participation in the 12th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference being held February 11-12, 2025 in Snowbird, Utah.

Positive
Zacks Investment Research
2 months ago
Here's Why Momentum in electroCore (ECOR) Should Keep going
If you are looking for stocks that are well positioned to maintain their recent uptrend, electroCore (ECOR) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Charts implemented using Lightweight Charts™